{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:53:03Z","timestamp":1781722383790,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ygyno.2020.01.005","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T18:18:46Z","timestamp":1578680326000},"page":"545-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial"],"prefix":"10.1016","volume":"156","author":[{"given":"Robert D.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0039-5041","authenticated-orcid":false,"given":"Marcia","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4200-0186","authenticated-orcid":false,"given":"Andrew R.","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurjees","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Orbegoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tugwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon J.S.","family":"Rustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon C.","family":"Jayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2020.01.005_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"17","key":"10.1016\/j.ygyno.2020.01.005_bb0010","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2020.01.005_bb0015","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2020.01.005_bb0020","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ygyno.2020.01.005_bb0025","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2020.01.005_bb0030","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.01.005_bb0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01954881","article-title":"Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4","volume":"45","author":"Pettit","year":"1989","journal-title":"Experientia"},{"issue":"1","key":"10.1016\/j.ygyno.2020.01.005_bb0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/np50049a016","article-title":"Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum","volume":"50","author":"Pettit","year":"1987","journal-title":"J. Nat. Prod."},{"issue":"15","key":"10.1016\/j.ygyno.2020.01.005_bb0045","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2003.05.186","article-title":"Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate","volume":"21","author":"Anderson","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2020.01.005_bb0050","first-page":"1829","article-title":"Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature","volume":"57","author":"Dark","year":"1997","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.ygyno.2020.01.005_bb0055","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1200\/JCO.2003.12.986","article-title":"Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow","volume":"21","author":"Stevenson","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2020.01.005_bb0060","first-page":"6413","article-title":"Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability","volume":"61","author":"Tozer","year":"2001","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ygyno.2020.01.005_bb0065","first-page":"1626","article-title":"Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues","volume":"59","author":"Tozer","year":"1999","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.ygyno.2020.01.005_bb0070","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1200\/JCO.2003.05.187","article-title":"Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging","volume":"21","author":"Galbraith","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2020.01.005_bb0075","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2003.05.185","article-title":"Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results","volume":"21","author":"Rustin","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"5794","key":"10.1016\/j.ygyno.2020.01.005_bb0080","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1126\/science.1127592","article-title":"Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors","volume":"313","author":"Shaked","year":"2006","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.ygyno.2020.01.005_bb0085","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2015.65.8153","article-title":"Randomized phase II evaluation of bevacizumab versus bevacizumab plus Fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: an NRG oncology\/gynecologic oncology group study","volume":"34","author":"Monk","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2020.01.005_bb0090","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-11-3376","article-title":"Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer","volume":"18","author":"Nathan","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2020.01.005_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.01.005_bb0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"17","key":"10.1016\/j.ygyno.2020.01.005_bb0105","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-13-3248","article-title":"The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer","volume":"20","author":"Backen","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2020.01.005_bb0110","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1038\/s41467-018-07174-1","article-title":"Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer","volume":"9","author":"Jayson","year":"2018","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ygyno.2020.01.005_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/bjc.2016.194","article-title":"Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab","volume":"115","author":"Zhou","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2020.01.005_bb0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1293\/tox.2018-0023","article-title":"Histopathological and functional changes in a single-dose model of combretastatin A4 disodium phosphate-induced myocardial damage in rats","volume":"31","author":"Tochinai","year":"2018","journal-title":"J. Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.01.005_bb0125","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1111\/vco.12327","article-title":"A dose-escalation study of combretastatin A4-phosphate in healthy dogs","volume":"16","author":"Abma","year":"2018","journal-title":"Vet. Comp. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.01.005_bb0130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.lungcan.2015.09.004","article-title":"Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial","volume":"90","author":"Addison","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2020.01.005_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41416-018-0132-8","article-title":"Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial","volume":"119","author":"Backen","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"10023","key":"10.1016\/j.ygyno.2020.01.005_bb0140","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ygyno.2020.01.005_bb0145","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-11-2414","article-title":"Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors","volume":"18","author":"Patterson","year":"2012","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:48:34Z","timestamp":1758772114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820300056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0090825820300056"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}